Perioperative SOX treatment significantly improved 3-year disease-free survival in patients with locally advanced gastric cancer compared with adjuvant CapOx. Read More ›

Results from a phase 2 clinical trial of the use of zanidatamab with standard first-line chemotherapy in patients with HER2-positive GEA show promising disease control rate and duration of response. Read More ›

Results from a second-line trastuzumab deruxtecan phase 2 study in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer reveal promising response and safety. Read More ›

Comprehensive analysis of immune checkpoints in gastric adenocarcinoma finds ICOSLG and CD70 may serve as prognostic biomarkers for gastric cancer. Read More ›

Updated clinical data from the PANTHERA study shows promising efficacy for pembrolizumab triple therapy in HER2-positive advanced gastric and gastroesophageal junction (GEJ) cancer regardless of a patient’s PD-L1 status. Read More ›

Three-year ATTRACTION-2 follow-up results confirm the long-term efficacy of nivolumab in patients with previously treated advanced gastric/gastroesophageal junction (GEJ) cancer. Read More ›

KEYNOTE-181 results show improved overall survival in patients with advanced esophageal cancer treated with second-line pembrolizumab compared with chemotherapy. Read More ›

Recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma were released by an expert panel. Read More ›

Differences in survival time by tumor response were found during evaluation of nivolumab therapy in advanced gastric cancer. Read More ›

The use of PET to direct therapy after nonresponse to induction chemotherapy improved overall survival in patients with resectable esophageal cancer. Read More ›